0000000000529299

AUTHOR

Alan Altraja

showing 3 related works from this author

Protocol for the EARCO Registry

2020

Rationale and objectives Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that leads to an increased risk of emphysema and liver disease. Despite extensive investigation, there remain unanswered questions concerning the natural history, pathophysiology, genetics and the prognosis of the lung disease in association with AATD. The European Alpha-1 Clinical Research Collaboration (EARCO) is designed to bring together researchers from European countries and to create a standardised database for the follow-up of patients with AATD. Study design and population The EARCO Registry is a non-interventional, multicentre, pan-European, longitudinal observational cohort study enrolling patie…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyChronic Obstructive Pulmonary DiseasePopulation1MEDLINElcsh:Medicine61032 Biomedical and Clinical Sciences610 Medicine & health[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract03 medical and health sciencesLiver diseaseStudy Protocol0302 clinical medicineRare DiseasesClinical ResearchmedicineGenetics030212 general & internal medicineIntensive care medicineeducation3202 Clinical SciencesLungProtocol (science)Emphysemaeducation.field_of_studybusiness.industryPreventionlcsh:Rmedicine.disease3. Good healthNatural historyClinical research030228 respiratory systemObservational study10178 Clinic for PneumologybusinessCohort study
researchProduct

Eosinophilic and Noneosinophilic Asthma

2021

Background Phenotypic characteristics of patients with eosinophilic and noneosinophilic asthma are not well characterized in global, real-life severe asthma cohorts. Research Question What is the prevalence of eosinophilic and noneosinophilic phenotypes in the population with severe asthma, and can these phenotypes be differentiated by clinical and biomarker variables? Study Design and Methods This was an historical registry study. Adult patients with severe asthma and available blood eosinophil count (BEC) from 11 countries enrolled in the International Severe Asthma Registry (January 1, 2015-September 30, 2019) were categorized according to likelihood of eosinophilic phenotype using a pre…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPopulationCritical Care and Intensive Care Medicine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineEosinophilicmedicine030212 general & internal medicineeducationAsthmaeducation.field_of_studybusiness.industryEosinophilmedicine.diseaseBenralizumab3. Good healthmedicine.anatomical_structure030228 respiratory systemchemistryExhaled nitric oxideCohortBiomarker (medicine)Cardiology and Cardiovascular MedicinebusinessChest
researchProduct

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

2021

OBJECTIVE: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping ri…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyRegistryMedDRAPeripheral edemaClinical practicePulmonary arterial hypertensionRiociguatlaw.inventionPulmonary hypertension03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicine030212 general & internal medicineAdverse effectHipertensió pulmonarRiociguatbusiness.industrymedicine.diseasePulmonary hypertensionClinical trial030228 respiratory systemPulmonary hemorrhagemedicine.symptomSafetybusinessmedicine.drug
researchProduct